Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-06-27

Clinical Trial Update: Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial update for memantine in chronic schizophrenia; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Memantine (memantine)

Snippet

Sponsor: M. Schaefer, MD | Conditions: Chronic Schizophrenia | Phase 3 | Status: TERMINATED